This page lists the SEC filings reported by Baker Brothers Advisors.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2024-04-23 | BAKER BROS. ADVISORS LP | TScan Therapeutics, Inc. | 2,828,938 | 6.1% | EDGAR |
| SC 13D | 2024-04-18 | BAKER BROS. ADVISORS LP | BICYCLE THERAPEUTICS plc | 7,689,243 | 19.9% | EDGAR |
| SC 13D | 2024-04-01 | BAKER BROS. ADVISORS LP | Kymera Therapeutics, Inc. | 5,997,706 | 9.8% | EDGAR |
| SC 13D/A | 2024-03-28 | BAKER BROS. ADVISORS LP | IGM Biosciences, Inc. | 4,145,706 | 12.4% | EDGAR |
| SC 13D/A | 2024-03-25 | BAKER BROS. ADVISORS LP | MADRIGAL PHARMACEUTICALS, INC. | 2,070,544 | 10.0% | EDGAR |
| SC 13D | 2024-03-05 | BAKER BROS. ADVISORS LP | vTv Therapeutics Inc. | 122,664 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | 2seventy bio, Inc. | 2,527,672 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Achilles Therapeutics plc | 3,311,567 | 8.1% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Aerovate Therapeutics, Inc. | 1,680,517 | 6.1% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Spyre Therapeutics, Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Aligos Therapeutics, Inc. | 3,664,013 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Aravive, Inc. | 3,863,568 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Biomea Fusion, Inc. | 2,108,949 | 5.9% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Cabaletta Bio, Inc. | 1,457,626 | 3.4% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Akero Therapeutics, Inc. | 2,368,378 | 4.3% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | HERON THERAPEUTICS, INC. /DE/ | 7,881,933 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Cyteir Therapeutics, Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | CERUS CORP | 19,477,339 | 10.7% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | HOOKIPA Pharma Inc. | 8,148,985 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Immatics N.V. | 5,838,853 | 6.9% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.